ABG
ANTX icon

Ally Bridge Group’s AN2 Therapeutics ANTX Stock Holding History

Ally Bridge Group’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.8M Buy
+526,315
New +$1.09M 1.45% 25

Other funds holding ANTX

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Ally Bridge Group's ANTX Position: Q1 2026 in Review

Ally Bridge Group opened a new position in AN2 Therapeutics (ANTX) in Q1 2026: 526,315 shares worth $1.8M. The stake represents 1.45% of the portfolio and ranks #25 among its holdings.

52 funds tracked by Wall St. Rank hold ANTX as of Q1 2026.

  • Ally Bridge Group held 526,315 shares of AN2 Therapeutics worth $1.8M as of Q1 2026.
  • AN2 Therapeutics was a new Ally Bridge Group position in Q1 2026.
  • AN2 Therapeutics made up 1.45% of Ally Bridge Group's portfolio in Q1 2026, its #25 holding.
  • 52 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q1 2026.

Based on Ally Bridge Group's 13F filing for Q1 2026, filed 18 May 2026.